T-Cell Immunotherapy Trial Could be Good News for Mesothelioma Patients

T-Cell Immunotherapy

The first four mesothelioma patients treated with a new kind of T-cell immunotherapy have responded well with few side effects.  That is the word from researchers working with the drug TC-210. TC-210 is a type of T cell therapy. It is made by TCR² Therapeutics. Malignant mesothelioma is one of several kinds of cancers that overproduce the protein mesothelin. In the Phase I trial, tumors regressed in all five cancer patients who received T-cell immunotherapy with TC-210.  Targeting Cancer with T-Cells T-cells are immune system cells that help fight cancer and other invaders. Mesothelioma and other cancers have ways of avoiding the body’s natural killer T-cell response. T-cell immunotherapy helps to turn it back on.  TC-210 is like a “living … Continue reading T-Cell Immunotherapy Trial Could be Good News for Mesothelioma Patients »

Low Dose Aspirin Could Increase Mesothelioma Risk

Low Dose Aspirin

If you are at risk for malignant mesothelioma, you may want to think twice about taking low dose aspirin on a regular basis.  A new study suggests that low dose aspirin could speed up the growth and spread of cancer cells in older people.  The study appears in the Journal of the National Cancer Institute. It involved more than 19,000 people in Australia and the US.  Low Dose Aspirin and Mesothelioma Many older people take small daily doses of aspirin to reduce their risk for heart attack. Aspirin reduces inflammation and the blood’s ability to clot. This makes it less likely to form the blockages that cause heart attacks and strokes.  But mounting evidence suggests that taking low dose aspirin … Continue reading Low Dose Aspirin Could Increase Mesothelioma Risk »

Gene Targeting Slows Aggressive Form of Pleural Mesothelioma

Aggressive Form of Pleural Mesothelioma

Scientists in Vienna are developing a new treatment for a particularly aggressive form of pleural mesothelioma.  This form of mesothelioma occurs in people with a genetic mutation. The mutation produces signals that fuel tumor growth. These patients typically have an even worse prognosis than other mesothelioma patients.  But the Austrian team came up with a way to block activation of the mutated gene. If the gene does not send its signal, this aggressive form of pleural mesothelioma may grow more slowly.  Aggression Fueled by Telomerase Malignant mesothelioma is one of the most aggressive kinds of cancer. It starts on the membranes around organs and can quickly spread to other parts of the body. By the time most people notice symptoms, … Continue reading Gene Targeting Slows Aggressive Form of Pleural Mesothelioma »

Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care

Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma.  All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004. But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma.  Checkpoint Inhibitors for Mesothelioma Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma. But this approach does … Continue reading Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care »

The Peritoneal Cancer Index in Mesothelioma Prognosis

peritoneal cancer index

The peritoneal cancer index is a valuable prognostic tool and should be considered in mesothelioma treatment planning. That is the word from a group of Finnish cancer researchers. They analyzed twelve years of data on peritoneal mesothelioma in their country. Mesothelioma patients with a higher peritoneal cancer index had a worse prognosis than those with a lower PCI. The group says cancer doctors ought to be including the PCI in their decision-making for people with peritoneal mesothelioma. What is the Peritoneal Cancer Index? Peritoneal mesothelioma makes up about a fifth of all mesothelioma cases. It grows on the peritoneum, a membrane that surrounds the abdominal organs. As cancer spreads, tumors can show up in other areas inside the peritoneal cavity.  … Continue reading The Peritoneal Cancer Index in Mesothelioma Prognosis »

Decisions About Pleural Effusion in Mesothelioma: New Tool May Help

Decisions about pleural effusion

Researchers in the UK have developed a new tool that may help patients with mesothelioma and other pleural cancers make decisions about pleural effusion.  Pleural effusion is the buildup of excess fluid in the space around the lungs. It is a common side effect in people with advanced lung or breast cancer or pleural mesothelioma.  It can be complicated and time-consuming to make decisions about pleural effusion treatment. There are many different ways to handle the problem.  The UK research team developed a web-based decision support tool with input from patients, clinicians, and caregivers. The tool uses videos and questions to help patients decide on the best course of treatment for their unique situation. Pleural Effusion and Treatment Options The pleura … Continue reading Decisions About Pleural Effusion in Mesothelioma: New Tool May Help »

Triple Therapy May Become New First-Line Treatment for Mesothelioma

First-Line Treatment for Mesothelioma

A combination of three powerful mesothelioma therapies could become a new first-line treatment for mesothelioma if an upcoming clinical trial is successful. The makers of the experimental immunotherapy drug ONCOS-102 announced the new clinical trial. It will enroll up to 100 mesothelioma patients from around the world.  The trial will test ONCOS-102 along with Keytruda (pembrolizumab) and standard chemotherapy. Keytruda is an immune checkpoint inhibitor. Both ONCOS-102 and Keytruda have shown some promise when combined with mesothelioma chemotherapy. Targovax hopes that the triple therapy approach will produce an even more powerful first-line treatment for mesothelioma. Clinic Trial of ONCOS-102 A first-line treatment is a treatment for mesothelioma patients who have not yet had any other therapies. Most patients start with … Continue reading Triple Therapy May Become New First-Line Treatment for Mesothelioma »

Managing Mesothelioma During the COVID-19 Pandemic: New Guidelines

Mesothelioma During the COVID-19 Pandemic

New guidance suggests that patients should continue to receive treatment for malignant mesothelioma during the COVID-19 pandemic. Two new reports include recommendations for hospitals to keep vulnerable patients safe. COVID-19 is especially dangerous for people with lung-related cancers like pleural mesothelioma. Their immune systems are not as strong as healthy people and their lungs are already damaged.  But two new reports suggests that it may be even riskier to put off treatment for lung cancers like mesothelioma during the COVID-19 pandemic.  How the Virus Could Impact Lung Cancer Patients Both of the new reports come from researchers in Pennsylvania. They focus on people with lung cancer rather than mesothelioma. But pleural mesothelioma is also a lung-related cancer. It carries many … Continue reading Managing Mesothelioma During the COVID-19 Pandemic: New Guidelines »

Benefits of Propolis: Could Bee Product Help Fight Mesothelioma?

Benefits of Propolis

A new review of the potential benefits of propolis suggests that this antioxidant-rich bee product might be a worthwhile addition to the fight against mesothelioma.  Bees produce propolis from the sap of evergreens. The research on this supplement is limited. There has never been a study on propolis and mesothelioma.  But a new Taiwanese review concludes that there is enough evidence on the benefits of propolis in several other types of cancer to warrant further study.  What is Propolis? Propolis is a sticky resin that bees produce to help protect their hives. It is made up of a combination of evergreen sap, bee saliva, and beeswax. Bees coat their hives with it. Many ancient civilizations believed in the health benefits … Continue reading Benefits of Propolis: Could Bee Product Help Fight Mesothelioma? »

BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis

BAP1 Expression and Mesothelioma Prognosis

A new report says the prognostic role of BAP1 expression in mesothelioma is not as cut-and-dried as some studies suggest. Italian researchers analyzed the cases of 698 patients with pleural mesothelioma. The group included 60 of their own patients and another 638 from other studies. Their analysis suggests that mesothelioma prognosis has more to do with subtype than with genetic BAP1 expression. They caution doctors not to put too much stock in a patient’s BAP1 status without also considering other factors. Genetic Alterations and Mesothelioma Survival Asbestos exposure is the primary cause of mesothelioma. But not everyone who is exposed to asbestos gets cancer. This may have to do with their genetic makeup. Certain genetic alterations may make a person … Continue reading BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis »

Get your free copy of
“Surviving Mesothelioma” Today!